Form 4: BAKER BROS. ADVISORS LP bought MDGL
BAKER BROS. ADVISORS LP (Director at MADRIGAL PHARMACEUTICALS, INC.) reported an open-market purchase of 91,806 shares of MDGL at an average $381.49, roughly $35,023,032, in a Form 4 filed 2026-11-06.
| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 3 | 3 | 3 | 100% | +3.9% | +3.9% |
| 3d | 5 | 5 | 2 | 40% | +3.0% | -0.4% |
| 1w | 5 | 5 | 2 | 40% | +1.4% | -3.9% |
| 1m | 3 | 3 | 3 | 100% | +4.6% | +4.6% |
| 3m | 0 | 0 | 0 | — | — | — |
| 6m | 0 | 0 | 0 | — | — | — |
| 1y | 0 | 0 | 0 | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
BAKER BROS. ADVISORS LP (Director at MADRIGAL PHARMACEUTICALS, INC.) reported an open-market purchase of 91,806 shares of MDGL at an average $381.49, roughly $35,023,032, in a Form 4 filed 2026-11-06.
BAKER BROS. ADVISORS LP (Director at Kodiak Sciences Inc.) reported an open-market purchase of 247,090 shares of KOD at an average $98.51, roughly $24,340,836, in a Form 4 filed 2026-11-06.
BAKER BROS. ADVISORS LP (Director at Kodiak Sciences Inc.) reported an open-market purchase of 715,592 shares of KOD at an average $88.59, roughly $63,397,609, in a Form 4 filed 2026-09-30.
BAKER BROS. ADVISORS LP (Director at Kodiak Sciences Inc.) reported an open-market purchase of 418,323 shares of KOD at an average $83.58, roughly $34,963,077, in a Form 4 filed 2026-09-30.
BAKER BROS. ADVISORS LP (Director at Kodiak Sciences Inc.) reported an open-market purchase of 807,840 shares of KOD at an average $72.57, roughly $58,625,708, in a Form 4 filed 2026-09-30.
End of results.